Cargando…

Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease

BACKGROUND: A residual risk of cardiovascular disease tends to persist despite standard prevention therapy with statins. This may stem partly from increased oxidized low-density lipoprotein (LDL) levels. However, how oxidized LDL can be further reduced beyond statin therapy in high-risk diabetes pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuda, Morihiro, Tamura, Ritsu, Kanno, Kotaro, Segawa, Takatsugu, Kinoshita, Haruyuki, Nishimoto, Orie, Nishiyama, Hirohiko, Kawamoto, Toshiharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029151/
https://www.ncbi.nlm.nih.gov/pubmed/24314067
http://dx.doi.org/10.1186/1758-5996-5-77
_version_ 1782317163308122112
author Matsuda, Morihiro
Tamura, Ritsu
Kanno, Kotaro
Segawa, Takatsugu
Kinoshita, Haruyuki
Nishimoto, Orie
Nishiyama, Hirohiko
Kawamoto, Toshiharu
author_facet Matsuda, Morihiro
Tamura, Ritsu
Kanno, Kotaro
Segawa, Takatsugu
Kinoshita, Haruyuki
Nishimoto, Orie
Nishiyama, Hirohiko
Kawamoto, Toshiharu
author_sort Matsuda, Morihiro
collection PubMed
description BACKGROUND: A residual risk of cardiovascular disease tends to persist despite standard prevention therapy with statins. This may stem partly from increased oxidized low-density lipoprotein (LDL) levels. However, how oxidized LDL can be further reduced beyond statin therapy in high-risk diabetes patients remains unclear. We aimed to clarify the clinical factors associated with oxidized LDL levels in statin-treated high-risk diabetes patients. METHODS: This cross-sectional observational study included 210 diabetes patients with coronary artery diseases (CAD) who were treated with statins. We determined serum malondialdehyde-modified LDL (MDA-LDL), LDL cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride (TG), remnant lipoprotein cholesterol, hemoglobin (Hb) A(1c), adiponectin, and C-reactive protein (CRP) levels and investigated the factors influencing the MDA-LDL level. RESULTS: In univariate analysis, the MDA-LDL level was significantly correlated with LDL cholesterol (p < 0.0001), TG (p < 0.0001), HDL cholesterol (p = 0.017), and adiponectin (p = 0.001) levels but not with age, body mass index, waist circumference, blood pressure, or HbA(1c) levels. Even after adjusting for the LDL cholesterol level, the correlations between the MDA-LDL level and the TG, HDL cholesterol, and adiponectin levels were still significant. Among these significant factors, multivariate analysis revealed that the MDA-LDL level was independently associated with the LDL cholesterol, TG, and HDL cholesterol but not with adiponectin levels. The MDA-LDL level was also significantly associated with the CRP level (p = 0.014) and the remnant lipoprotein cholesterol level (p < 0.0001) independently of the LDL cholesterol level. The number of metabolic syndrome (MS) components was significantly associated with the MDA-LDL/LDL cholesterol ratio (p < 0.0001). Furthermore, the use of metformin and α-glucosidase inhibitors was inversely associated with high MDA-LDL levels (p = 0.033 and 0.018, respectively). CONCLUSION: In statin-treated diabetes patients with CAD, the MDA-LDL level was significantly correlated with TG and HDL cholesterol levels. Adiponectin level was also significantly associated with the MDA-LDL level, but not independent of the above-mentioned factors. The management of dyslipidemic MS components, including the use of metformin or α-glucosidase inhibitors, may be important for reducing the oxidized LDL levels beyond statin therapy in high-risk diabetes patients.
format Online
Article
Text
id pubmed-4029151
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40291512014-05-22 Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease Matsuda, Morihiro Tamura, Ritsu Kanno, Kotaro Segawa, Takatsugu Kinoshita, Haruyuki Nishimoto, Orie Nishiyama, Hirohiko Kawamoto, Toshiharu Diabetol Metab Syndr Research BACKGROUND: A residual risk of cardiovascular disease tends to persist despite standard prevention therapy with statins. This may stem partly from increased oxidized low-density lipoprotein (LDL) levels. However, how oxidized LDL can be further reduced beyond statin therapy in high-risk diabetes patients remains unclear. We aimed to clarify the clinical factors associated with oxidized LDL levels in statin-treated high-risk diabetes patients. METHODS: This cross-sectional observational study included 210 diabetes patients with coronary artery diseases (CAD) who were treated with statins. We determined serum malondialdehyde-modified LDL (MDA-LDL), LDL cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride (TG), remnant lipoprotein cholesterol, hemoglobin (Hb) A(1c), adiponectin, and C-reactive protein (CRP) levels and investigated the factors influencing the MDA-LDL level. RESULTS: In univariate analysis, the MDA-LDL level was significantly correlated with LDL cholesterol (p < 0.0001), TG (p < 0.0001), HDL cholesterol (p = 0.017), and adiponectin (p = 0.001) levels but not with age, body mass index, waist circumference, blood pressure, or HbA(1c) levels. Even after adjusting for the LDL cholesterol level, the correlations between the MDA-LDL level and the TG, HDL cholesterol, and adiponectin levels were still significant. Among these significant factors, multivariate analysis revealed that the MDA-LDL level was independently associated with the LDL cholesterol, TG, and HDL cholesterol but not with adiponectin levels. The MDA-LDL level was also significantly associated with the CRP level (p = 0.014) and the remnant lipoprotein cholesterol level (p < 0.0001) independently of the LDL cholesterol level. The number of metabolic syndrome (MS) components was significantly associated with the MDA-LDL/LDL cholesterol ratio (p < 0.0001). Furthermore, the use of metformin and α-glucosidase inhibitors was inversely associated with high MDA-LDL levels (p = 0.033 and 0.018, respectively). CONCLUSION: In statin-treated diabetes patients with CAD, the MDA-LDL level was significantly correlated with TG and HDL cholesterol levels. Adiponectin level was also significantly associated with the MDA-LDL level, but not independent of the above-mentioned factors. The management of dyslipidemic MS components, including the use of metformin or α-glucosidase inhibitors, may be important for reducing the oxidized LDL levels beyond statin therapy in high-risk diabetes patients. BioMed Central 2013-12-06 /pmc/articles/PMC4029151/ /pubmed/24314067 http://dx.doi.org/10.1186/1758-5996-5-77 Text en Copyright © 2013 Matsuda et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Matsuda, Morihiro
Tamura, Ritsu
Kanno, Kotaro
Segawa, Takatsugu
Kinoshita, Haruyuki
Nishimoto, Orie
Nishiyama, Hirohiko
Kawamoto, Toshiharu
Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease
title Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease
title_full Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease
title_fullStr Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease
title_full_unstemmed Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease
title_short Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease
title_sort impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029151/
https://www.ncbi.nlm.nih.gov/pubmed/24314067
http://dx.doi.org/10.1186/1758-5996-5-77
work_keys_str_mv AT matsudamorihiro impactofdyslipidemiccomponentsofmetabolicsyndromeadiponectinlevelsandantidiabetesmedicationsonmalondialdehydemodifiedlowdensitylipoproteinlevelsinstatintreateddiabetespatientswithcoronaryarterydisease
AT tamuraritsu impactofdyslipidemiccomponentsofmetabolicsyndromeadiponectinlevelsandantidiabetesmedicationsonmalondialdehydemodifiedlowdensitylipoproteinlevelsinstatintreateddiabetespatientswithcoronaryarterydisease
AT kannokotaro impactofdyslipidemiccomponentsofmetabolicsyndromeadiponectinlevelsandantidiabetesmedicationsonmalondialdehydemodifiedlowdensitylipoproteinlevelsinstatintreateddiabetespatientswithcoronaryarterydisease
AT segawatakatsugu impactofdyslipidemiccomponentsofmetabolicsyndromeadiponectinlevelsandantidiabetesmedicationsonmalondialdehydemodifiedlowdensitylipoproteinlevelsinstatintreateddiabetespatientswithcoronaryarterydisease
AT kinoshitaharuyuki impactofdyslipidemiccomponentsofmetabolicsyndromeadiponectinlevelsandantidiabetesmedicationsonmalondialdehydemodifiedlowdensitylipoproteinlevelsinstatintreateddiabetespatientswithcoronaryarterydisease
AT nishimotoorie impactofdyslipidemiccomponentsofmetabolicsyndromeadiponectinlevelsandantidiabetesmedicationsonmalondialdehydemodifiedlowdensitylipoproteinlevelsinstatintreateddiabetespatientswithcoronaryarterydisease
AT nishiyamahirohiko impactofdyslipidemiccomponentsofmetabolicsyndromeadiponectinlevelsandantidiabetesmedicationsonmalondialdehydemodifiedlowdensitylipoproteinlevelsinstatintreateddiabetespatientswithcoronaryarterydisease
AT kawamototoshiharu impactofdyslipidemiccomponentsofmetabolicsyndromeadiponectinlevelsandantidiabetesmedicationsonmalondialdehydemodifiedlowdensitylipoproteinlevelsinstatintreateddiabetespatientswithcoronaryarterydisease